January 6: NL005 Granted U.S. and South Korean Invention Patents

April 28: NORTHLAND Wins the Third Prize of the Beijing Science and Technology Award

May 9: Beijing Northland Biotechnology Co., Ltd., Beijing Northland Pharmaceutical Technology Co., Ltd., South Korea's Humedix Co., Ltd., and Beijing Lint Pharmaceutical Technology Co., Ltd. held a signing ceremony in Beijing for a joint investment agreement to establish a Sino-foreign joint venture.

February 12: NORTHLAND's NL003 project was selected as one of the Top Ten Enterprise Technological Innovation Achievements of Zhongguancun for 2009.

April 22: NORTHLAND was honored as the "Unit with Outstanding Contributions to the Industrialization of Major Scientific and Technological Achievements in 2009 in the Zhongguancun National Independent Innovation Demonstration Zone."

April 29: NL002 completed Phase II clinical trials, and the Phase III clinical trial received the “Notice of Acceptance of Drug Registration Application.”

August 20: The company was selected as one of the first key enterprises to be cultivated under the “Gazelle Program” of the Zhongguancun National Independent Innovation Demonstration Zone.

February 18: The company was listed on the Share Quotation and Transfer System for Non-Listed Joint-Stock Companies in the Zhongguancun Science Park of the Shenzhen Stock Exchange (“New Third Board”).

March 25: The NL003 project received FDA approval from the U.S. for Phase I/II clinical trials for the treatment of diabetic peripheral neuropathy (BB IND 13,938) and for the treatment of myocardial infarction (BB IND 13,948).

May 6: The NL005 project, “Thymosin β4 Derivatives and Their Applications,” has been granted a Chinese invention patent.

August 24: Certified as a Beijing Science and Technology Research and Development Institution

December 24: Three of the company’s new drug projects have been approved as key research topics under the “Eleventh Five-Year Plan” National Major New Drug Development Program.

December 17: The company was awarded the title of “100 Innovative Enterprises” in the Zhongguancun Science Park.

June 3: The NL003 project has passed the review by the National Medical Products Administration and has officially entered Phase I clinical trials.

June 16: Beijing Northland Biotechnology Co., Ltd. successfully restructured into Beijing Northland Biotechnology Co., Ltd., with its registered capital increasing from the original 2 million yuan to 9.5 million yuan.

October 31: Phase I clinical trial of NL003 project launched.

December 31: Approved as a high-tech enterprise under the new version.

January 17: The NL003 project was selected as a topic under the 2006 “Haidian Park Special Development Fund—Special Fund for the Internationalization of Small and Medium-sized Enterprises.”

February 9: The NL002IIa clinical trial has been successfully completed.

May 30: The Phase IIb clinical trial of NL002 has been fully launched.

July 1: The NL003 project has passed the drug registration inspection conducted by the China National Institute for Drug and Biological Products Control.

April 5: A delegation of five people, including Mr. Ikunosuke Kato, President of TAKARA BIO INC., visited the company and engaged in thorough discussions and exchanges regarding future mutual technological cooperation.

September 2: The kickoff meeting for the Phase II clinical trial of the NL002 project was held.

October 31: NL003 received clinical trial approval from the Korea Food & Drug Administration.

January 21: With approval from the Beijing Municipal Intellectual Property Office, the company was selected as one of the 100 pilot enterprises for the 2005 Zhongguancun Science and Technology Park “Patent Engine” Program.

March 9: Mr. Hitoshi Kamiya from Itochu Corporation of Japan visited our company. Through mutual exchanges and in-depth discussions, both sides expressed great confidence and anticipation for further cooperation in the future.

April 8: NORTHLAND and the Affiliated Hospital of Chengde Medical College jointly held an academic conference on "Gene Therapy and Ischemic Diseases." NORTHLAND and the Affiliated Hospital of Chengde Medical College signed a cooperation agreement regarding the pharmacodynamic evaluation of NL003.

April 9: A delegation of four people, including Mr. Kim Sun-young, Professor at the Institute of Genetic Engineering at Seoul National University in South Korea and President of ViroMed, paid a two-day visit to NORTHLAND and reached a consensus on mutually promoting new drug development.

September 15: The 15th National Invention Exhibition was held at the China Agricultural Exhibition Hall. NORTHLAND's NL003 new drug project participated in the exhibition and received great attention and positive feedback from visitors.

November 9: NORTHLAND's NL003 project received a non-repayable grant of 750,000 yuan from the National Science and Technology Innovation Fund for Small and Medium-sized Enterprises in 2005 (project approval code 05C26221100005).